Latest Smith, Kline & French Stories
- Local Nonprofits Improving Community Health Encouraged to Apply for Ten $40,000 Awards PHILADELPHIA, April 17, 2013 /PRNewswire/ -- GlaxoSmithKline (@GSKUS) today issued the 2013 GSK IMPACT Awards Call for Applications. This annual awards program will honor up to ten local nonprofits in the Greater Philadelphia Region with $40,000 each in recognition of their achievements and innovations in improving community health. "At a time when so many families and communities are...
LONDON, July 25, 2012 /PRNewswire/ -- Pharmaceutical group GlaxoSmithKline concedes pricing pressure in Europe had affected overall performance in the second quarter but says the Group was making "good progress" against its strategic agenda. In a video interview, CEO Sir Andrew Witty said he had seen strong performances in the Emerging Markets, Japan and the group's Consumer business. Looking forward he said he now expected full-year 2012 to be in line with 2011 as the...
Lawrence LeBlond for redOrbit.com - Your Universe Online British pharmaceutical giant GlaxoSmithKline (GSK) has acquired US-based Human Genome Sciences (HGS) after tough negotiations saw it raise offers from an initial $2.6 billion in April, putting the final value of the deal at $3.6 billion or $14.25 per share. By securing HGS, GSK is gaining full control of the drug Benlysta, the first drug in more than 50 years to be approved by the Food and Drug Administration (FDA) for the...
LONDON and PHILADELPHIA, July 2, 2012 /PRNewswire/ -- GlaxoSmithKline plc (GSK) today announced that it has reached an agreement with the US Government, multiple states and the District of Columbia to conclude the Company's most significant ongoing Federal government investigations. The final settlement is a result of negotiations which reached agreement in principle in November 2011. GSK will make payments totalling $3bn which are covered by existing provisions and will be...
STAMFORD, Conn., June 11, 2012 /PRNewswire-USNewswire/-- AmeriCares has presented its annual Power of Partnership Award to GlaxoSmithKline (GSK) in recognition of the company's outstanding commitment to aiding disaster survivors and increasing access to health care around the world. GSK consistently supports AmeriCares with donated medicines, including a remarkable Produce to Give program that allows the aid organization to select $4 million worth of the most critically needed...
MALVERN, Pa. and PHILADELPHIA, May 21, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc (LSE: GSK), announced today that they have entered into an agreement for the co-promotion of Testim® 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone. (Logo:...
LONDON and PHILADELPHIA, March 20, 2012 /PRNewswire/ -- GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit - risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III...
LONDON, February 7, 2012 /PRNewswire/ -- In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned to continue to deliver. Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth. "This is a...
TORONTO, Nov. 10, 2011 /PRNewswire/ - GlaxoSmithKline Inc. (GSK) today announced the launch of the GSK Canada Life Sciences Innovation Fund, a new national $50 million fund that will significantly advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research. The fund will identify strategic investment opportunities within Canada's life sciences industry including academic and health institutions, translational research centres...
PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A). The agreement provides Signum with research support and milestone payments. GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and...
